KR20220030934A - 항-gal9 면역-억제 결합 분자 - Google Patents

항-gal9 면역-억제 결합 분자 Download PDF

Info

Publication number
KR20220030934A
KR20220030934A KR1020217040007A KR20217040007A KR20220030934A KR 20220030934 A KR20220030934 A KR 20220030934A KR 1020217040007 A KR1020217040007 A KR 1020217040007A KR 20217040007 A KR20217040007 A KR 20217040007A KR 20220030934 A KR20220030934 A KR 20220030934A
Authority
KR
South Korea
Prior art keywords
gal9
antigen binding
binding molecule
cdrs
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217040007A
Other languages
English (en)
Korean (ko)
Inventor
미셸 와익스
딜립 케이. 풀루쿠낫
Original Assignee
더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 filed Critical 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치
Publication of KR20220030934A publication Critical patent/KR20220030934A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020217040007A 2019-05-31 2020-05-29 항-gal9 면역-억제 결합 분자 Pending KR20220030934A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962855590P 2019-05-31 2019-05-31
US62/855,590 2019-05-31
US201962900105P 2019-09-13 2019-09-13
US62/900,105 2019-09-13
PCT/AU2020/050546 WO2020237320A1 (en) 2019-05-31 2020-05-29 Anti-gal9 immune-inhibiting binding molecules

Publications (1)

Publication Number Publication Date
KR20220030934A true KR20220030934A (ko) 2022-03-11

Family

ID=73552467

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217040007A Pending KR20220030934A (ko) 2019-05-31 2020-05-29 항-gal9 면역-억제 결합 분자

Country Status (10)

Country Link
US (1) US20220227873A1 (https=)
EP (1) EP3976102A4 (https=)
JP (2) JP7797203B2 (https=)
KR (1) KR20220030934A (https=)
CN (1) CN114025797A (https=)
AU (1) AU2020285369A1 (https=)
CA (1) CA3141640A1 (https=)
IL (1) IL288561A (https=)
SG (1) SG11202113132YA (https=)
WO (1) WO2020237320A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220235135A1 (en) * 2019-05-31 2022-07-28 The Council Of The Queensland Institute Of Medical Research Activating anti-gal9 binding molecules
CR20240489A (es) * 2022-05-13 2025-01-07 Exelixis Inc Agentes aglutinantes 5t4 y usos de los mismos
PE20252168A1 (es) * 2023-01-27 2025-09-04 Exelixis Inc Agentes de union nkg2a y usos de estos
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2511085A1 (en) * 1993-03-05 1994-09-15 Universite Catholique De Louvain Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation
AU2002306849A1 (en) * 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
WO2003033709A2 (en) * 2001-10-17 2003-04-24 Bayer Healthcare Ag Regulation of human serine/threonine protein kinase
WO2010084999A1 (en) * 2009-01-26 2010-07-29 Protegene, Inc. Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases
AR080795A1 (es) * 2010-03-24 2012-05-09 Genentech Inc Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
WO2016008005A1 (en) * 2014-07-14 2016-01-21 The Council Of The Queensland Institute Of Medical Research Galectin immunotherapy
CA3080120C (en) * 2017-10-27 2023-11-21 New York University Anti-galectin-9 antibodies and uses thereof

Also Published As

Publication number Publication date
JP2025146842A (ja) 2025-10-03
JP2022534433A (ja) 2022-07-29
US20220227873A1 (en) 2022-07-21
EP3976102A4 (en) 2023-07-12
CA3141640A1 (en) 2020-12-03
EP3976102A1 (en) 2022-04-06
WO2020237320A1 (en) 2020-12-03
CN114025797A (zh) 2022-02-08
SG11202113132YA (en) 2021-12-30
AU2020285369A1 (en) 2021-12-23
JP7797203B2 (ja) 2026-01-13
IL288561A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
TWI718206B (zh) Pd-l1抗體、其抗原結合片段及其醫藥用途
JP6839772B2 (ja) 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体
JP2022071087A (ja) 抗ｃｄ３８抗体および使用方法
TWI585102B (zh) 拮抗ｃｄ４０ｌ之抗體多肽
TW202344516A (zh) 抗ｃｄ３９抗體、包含抗ｃｄ３９抗體之組成物及使用抗ｃｄ３９抗體之方法
CN110167966A (zh) 程序性细胞死亡(pd-1)的单结构域抗体
JP7747911B2 (ja) ＮＫｐ４６に結合するナチュラルキラー（ＮＫ）細胞エンゲージャー及びＦＣエンジニアリングを有するＢＣＭＡ変異体
JP2018533371A (ja) 抗ｔｉｇｉｔ抗原結合タンパク質と、その使用方法
JP7797203B2 (ja) 抗ｇａｌ９免疫阻害性結合分子
KR20200123164A (ko) Lag3 및 pd1에 결합하는 치료 분자
JP2022516351A (ja) 抗ｔｉｇｉｔ抗体
IL307336A (en) Novel tnfr2 binding molecules
JP2025542239A (ja) 自己免疫疾患の治療
US20220235135A1 (en) Activating anti-gal9 binding molecules
WO2025054328A1 (en) Bispecific binding construct capable of binding to ackr4, compositions comprising a bispecific binding construct capable of binding to ackr4, and methods of using bispecific binding construct capable of binding to ackr4
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение
WO2024078558A1 (zh) 抗cd100抗体及其用途
CN120882746A (zh) 结合至nkg2a和pd-l1的药剂及其用途
HK40027182B (zh) 抗tigit抗体

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000